Literature DB >> 16520651

Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2).

Abdelhakim Ahmed-Belkacem1, Alexandre Pozza, Sira Macalou, José M Pérez-Victoria, Ahcéne Boumendjel, Attilio Di Pietro.   

Abstract

Breast cancer resistance protein (BCRP/ABCG2) belongs to the ATP-binding cassette (ABC) transporter superfamily. It is able to efflux a broad range of anti-cancer drugs through the cellular membrane, thus limiting their anti-proliferative effects. Due to its relatively recent discovery in 1998, and in contrast to the other ABC transporters P-glycoprotein (MDR1/ABCB1) and multidrug resistance-associated protein (MRP1/ABCC1), only a few BCRP inhibitors have been reported. This review summarizes the known classes of inhibitors that are either specific for BCRP or also inhibit the other multidrug resistance ABC transporters. Information is presented on structure-activity relationship aspects and how modulators may interact with BCRP.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16520651     DOI： 10.1097/00001813-200603000-00001

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN： 0959-4973            Impact factor:   2.248


  28 in total

1.  5,7-Dimethoxyflavone and multiple flavonoids in combination alter the ABCG2-mediated tissue distribution of mitoxantrone in mice.

Authors:  Guohua An; Fang Wu; Marilyn E Morris
Journal:  Pharm Res       Date:  2011-01-29       Impact factor: 4.200

2.  Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.

Authors:  Yimao Zhang; Youngjoo Byun; Yunzhao R Ren; Jun O Liu; John Laterra; Martin G Pomper
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

3.  Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity.

Authors:  Glaucio Valdameri; Charlotte Gauthier; Raphaël Terreux; Rémy Kachadourian; Brian J Day; Sheila M B Winnischofer; Maria E M Rocha; Véronique Frachet; Xavier Ronot; Attilio Di Pietro; Ahcène Boumendjel
Journal:  J Med Chem       Date:  2012-04-02       Impact factor: 7.446

4.  Effects of single and multiple flavonoids on BCRP-mediated accumulation, cytotoxicity and transport of mitoxantrone in vitro.

Authors:  Guohua An; Marilyn E Morris
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

Review 5.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Authors:  Karthika Natarajan; Yi Xie; Maria R Baer; Douglas D Ross
Journal:  Biochem Pharmacol       Date:  2012-01-11       Impact factor: 5.858

Review 6.  Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).

Authors:  Zhanglin Ni; Zsolt Bikadi; Mark F Rosenberg; Qingcheng Mao
Journal:  Curr Drug Metab       Date:  2010-09       Impact factor: 3.731

7.  In vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs.

Authors:  Hong-May Sim; Chung-Pu Wu; Suresh V Ambudkar; Mei-Lin Go
Journal:  Biochem Pharmacol       Date:  2011-08-17       Impact factor: 5.858

8.  Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.

Authors:  Upal Roy; Geetika Chakravarty; Kerstin Honer Zu Bentrup; Debasis Mondal
Journal:  Biol Pharm Bull       Date:  2009-12       Impact factor: 2.233

9.  Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant.

Authors:  L Hu; C McArthur; R B Jaffe
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

10.  Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells.

Authors:  Hui Peng; Jing Qi; Zizheng Dong; Jian-Ting Zhang
Journal:  PLoS One       Date:  2010-12-07       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.